2022
Breast implant‐associated anaplastic large‐cell lymphoma: A series of two case reports diagnosed by cytopathology
Hrones M, Harigopal M, Xu M, Abi‐Raad R. Breast implant‐associated anaplastic large‐cell lymphoma: A series of two case reports diagnosed by cytopathology. Diagnostic Cytopathology 2022, 51: e25-e27. PMID: 36066320, DOI: 10.1002/dc.25052.Peer-Reviewed Original ResearchConceptsBreast implant-associated anaplastic large cell lymphomaImplant-associated anaplastic large cell lymphomaRare T-cell lymphomaAnaplastic large cell lymphomaPeri-implant effusionT-cell lymphomaLarge cell lymphomaCommon presentationDefinite treatmentBetter prognosisCase reportCytopathologic findingsCytopathologic analysisImplant removalEarly diagnosisFluid collectionBreast implantsCytopathological examinationLymphomaReportPatientsPrognosisEffusionDiseaseDiagnosisFurther Characterization of Clinicopathologic Features of Cystic Neutrophilic Granulomatous Mastitis
Liang Y, Zhan H, Krishnamurti U, Harigopal M, Sun T. Further Characterization of Clinicopathologic Features of Cystic Neutrophilic Granulomatous Mastitis. American Journal Of Clinical Pathology 2022, 158: 488-493. PMID: 35899981, DOI: 10.1093/ajcp/aqac074.Peer-Reviewed Original ResearchConceptsCystic neutrophilic granulomatous mastitisGranulomatous mastitisClinicopathologic characteristicsClinicopathologic featuresHigher Breast Imaging ReportingUnique infectious diseaseHospital-based cohortDistinct clinicopathologic featuresMass-like lesionCase-control studyData System scoreBreast Imaging ReportingPainful lesionsRadiologic studiesClinicopathologic profileSystem scoreImaging ReportingDemographic featuresInfectious diseasesPatientsLesionsDiseaseMastitisFurther characterizationSmokersExamination of Low ERBB2 Protein Expression in Breast Cancer Tissue
Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncology 2022, 8: 1-4. PMID: 35113160, PMCID: PMC8814969, DOI: 10.1001/jamaoncol.2021.7239.Peer-Reviewed Original ResearchConceptsBreast cancer biopsiesT-DXdCancer biopsiesLarge randomized clinical trialsRandomized clinical trialsERBB2 protein expressionCentral pathology laboratoryBreast cancer tissuesAmerican Pathologists surveysStudy of concordanceTrastuzumab deruxtecanERBB2 positivityPatient populationClinical trialsScore 0Breast cancerImmunohistochemistry scoreCancer tissuesIHC assaysPatientsPathology laboratoryProtein expressionBiopsyIHCConcordance
2020
Perniosis during the COVID‐19 pandemic: Negative anti‐SARS‐CoV‐2 immunohistochemistry in six patients and comparison to perniosis before the emergence of SARS‐CoV‐2
Ko CJ, Harigopal M, Damsky W, Gehlhausen JR, Bosenberg M, Patrignelli R, McNiff JM. Perniosis during the COVID‐19 pandemic: Negative anti‐SARS‐CoV‐2 immunohistochemistry in six patients and comparison to perniosis before the emergence of SARS‐CoV‐2. Journal Of Cutaneous Pathology 2020, 47: 997-1002. PMID: 32745281, PMCID: PMC7436569, DOI: 10.1111/cup.13830.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 nucleocapsid proteinPerivascular lymphocytesImmunohistochemical stainingCOVID-19 pandemicSARS-CoV-2 immunohistochemistryNucleocapsid proteinSARS-CoV-2Inflammatory lesionsHistopathologic findingsIntravascular occlusionMicroscopic findingsPerniosisIntravascular materialLymphocytesLesionsPatientsStainingPandemicSuch casesCuffingHistopathologyCasesImmunohistochemistryFindingsProteinEnumeration and molecular characterization of circulating tumor cells as an innovative tool for companion diagnostics in breast cancer
Harigopal M, Kowalski D, Vosoughi A. Enumeration and molecular characterization of circulating tumor cells as an innovative tool for companion diagnostics in breast cancer. Expert Review Of Molecular Diagnostics 2020, 20: 815-828. PMID: 32546017, DOI: 10.1080/14737159.2020.1784009.Peer-Reviewed Original ResearchConceptsBreast cancerTumor cellsCTC enumerationCTC detectionCTC clustersMetastatic breast cancerBreast cancer patientsEnumeration of CTCsOverall survivalRisk stratificationMetastatic sitesPeripheral bloodCancer patientsCTC levelsClinical backgroundPrimary siteClinical useCancerTumor phenotypeCompanion diagnosticsTumor heterogeneityDistant sitesMolecular characterizationPatientsPredictive importance
2017
Can Tumor Biology Predict Occult Multifocal Disease in Breast Cancer Patients?
Chagpar AB, Cicek AF, Harigopal M. Can Tumor Biology Predict Occult Multifocal Disease in Breast Cancer Patients? The American Surgeon 2017, 83: 704-708. PMID: 28738939, DOI: 10.1177/000313481708300725.Peer-Reviewed Original ResearchConceptsBreast cancer patientsNegative marginsCancer patientsPrimary tumor markersInvasive tumor sizePrimary tumor tissuesMedian invasive tumor sizeInitial surgeryOccult cancerOccult diseaseProspective trialInitial resectionMultifocal diseasePartial mastectomyDuctal carcinomaTumor sizeCavity shavesStage 0Independent pathologistsTumor markersTissue microarrayFurther diseasePatientsTumor tissueDiseaseEconomic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients
Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP. Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients. Annals Of Surgery 2017, 265: 39-44. PMID: 27192352, PMCID: PMC5605915, DOI: 10.1097/sla.0000000000001799.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularConnecticutFemaleFollow-Up StudiesHealth ExpendituresHospital CostsHumansMargins of ExcisionMastectomy, SegmentalMiddle AgedProspective StudiesReoperationSingle-Blind MethodTreatment OutcomeConceptsCavity shave marginsStandard partial mastectomyPartial mastectomyRe-excision ratesIndex surgeryInitial surgeryBreast cancerHospital perspectiveLower re-excision ratesDirect hospital costsBreast cancer patientsOperating room timeReoperative surgeryBaseline characteristicsOperative timePositive marginsShave marginsCancer patientsHospital costsStage 0Room timeSurgeryPathology costsPatientsMastectomy
2015
A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer
Chagpar AB, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Pusztai L, Horowitz NR. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. New England Journal Of Medicine 2015, 373: 503-510. PMID: 26028131, PMCID: PMC5584380, DOI: 10.1056/nejmoa1504473.Peer-Reviewed Original ResearchConceptsCavity shave marginsPositive marginsPartial mastectomyShave marginsDuctal carcinomaBreast cancerInvasive cancerOutcome measuresStandard partial mastectomySecondary outcome measuresPrimary outcome measureLower ratesRoutine resectionMedian ageClinicopathological characteristicsCavity shavingMargin clearanceSecond surgeryInvasive carcinomaStage 0MastectomyPathological testingPatientsFurther diseaseVolume of tissue
2011
Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells
Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL. Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells. Journal Of Clinical Oncology 2011, 29: 2978-2984. PMID: 21709197, PMCID: PMC3157961, DOI: 10.1200/jco.2010.32.9706.Peer-Reviewed Original ResearchConceptsER-positive patientsEstrogen receptorQuantitative immunofluorescenceBreast cancerTissue microarrayPositive cellsIndependent retrospective cohortsEstrogen receptor measurementsAssessment of survivalTMA cohortFalse-negative resultsRetrospective cohortER immunoreactivityTest discordancePrognostic outcomesIndependent cohortReceptor measurementsLimitations of immunohistochemistryPatientsDiscrepant casesCohortIHC methodPathologists' judgmentsDiscrepant resultsStandardized assaysComparison of Affirm VPIII and Papanicolaou Tests in the Detection of Infectious Vaginitis
Levi AW, Harigopal M, Hui P, Schofield K, Chhieng DC. Comparison of Affirm VPIII and Papanicolaou Tests in the Detection of Infectious Vaginitis. American Journal Of Clinical Pathology 2011, 135: 442-447. PMID: 21350100, DOI: 10.1309/ajcp7tbn5vzuglzu.Peer-Reviewed Original ResearchConceptsAffirm VPIIIPap testPapanicolaou testRoutine Pap testRoutine Papanicolaou testCandida speciesSensitive diagnostic testInfectious vaginitisLarge academic institutionPatient populationTrichomonas infectionBacterial vaginosisCandida vaginitisG vaginalisT vaginalisStudy populationHigh incidenceDiagnostic testsMolecular testsPatientsVaginitisVaginalisMorphologic identificationVaginosisCandidiasis
2010
Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome. American Journal Of Pathology 2010, 176: 1639-1647. PMID: 20150438, PMCID: PMC2843456, DOI: 10.2353/ajpath.2010.090711.Peer-Reviewed Original ResearchConceptsDisease-free survivalEstrogen receptorContinuous variablesSouthwest Oncology GroupAQUA methodAC chemotherapyMenopausal statusNegative patientsOncology GroupNode statusSequential doxorubicinPoor outcomeTumor sizeProgesterone receptorPrognostic informationWorse outcomesTissue biomarkersTissue microarrayBiphasic effectP53 expressionPatientsHER2Low expressersDiagnostic approachMultiplexed assessment
2006
Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays
Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL. Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays. Clinical Cancer Research 2006, 12: 6459-6468. PMID: 17085660, DOI: 10.1158/1078-0432.ccr-06-1383.Peer-Reviewed Original ResearchConceptsBreast cancerPatient outcomesTissue microarraySubset of patientsBreast cancer patientsTissue microarray platformInternal validation setRoutine pathology laboratoriesCancer patientsEstrogen receptorTissue biomarkersIndependent cohortTumor subtypesPredictive valueAcid-base analysisPathology laboratoryRNA expression studiesCancerTissue sectionsPatientsCohortOutcomesFurther validationObjective quantitative analysisBiomarker discovery
2004
Molecular predictors for response to carboplatinum and paclitaxel (CP) chemotherapy in patients with ovarian cancer
Psyrri A, Bamias A, Yu Z, Markakis S, Kowalski D, Weinberger P, Harigopal M, Efstathiou E, Rimm D, Dimopoulos M. Molecular predictors for response to carboplatinum and paclitaxel (CP) chemotherapy in patients with ovarian cancer. Journal Of Clinical Oncology 2004, 22: 5066-5066. DOI: 10.1200/jco.2004.22.14_suppl.5066.Peer-Reviewed Original ResearchMolecular predictors for response to carboplatinum and paclitaxel (CP) chemotherapy in patients with ovarian cancer
Psyrri A, Bamias A, Yu Z, Markakis S, Kowalski D, Weinberger P, Harigopal M, Efstathiou E, Rimm D, Dimopoulos M. Molecular predictors for response to carboplatinum and paclitaxel (CP) chemotherapy in patients with ovarian cancer. Journal Of Clinical Oncology 2004, 22: 5066-5066. DOI: 10.1200/jco.2004.22.90140.5066.Peer-Reviewed Original ResearchFine‐needle aspiration of Riedel's disease: Report of a case and review of the literature
Harigopal M, Sahoo S, Recant WM, DeMay RM. Fine‐needle aspiration of Riedel's disease: Report of a case and review of the literature. Diagnostic Cytopathology 2004, 30: 193-197. PMID: 14986301, DOI: 10.1002/dc.10420.Peer-Reviewed Original ResearchConceptsRiedel's diseaseFine-needle aspirationBilateral subtotal thyroidectomyForms of thyroiditisBland spindle-shaped cellsFrozen section diagnosisSpindle-shaped cellsGranulomatous thyroiditisSubtotal thyroidectomyRight lobeRiedel's thyroiditisHashimoto's thyroiditisCytological findingsJugular vesselsModerate cellularityThyroiditisCytomorphological featuresSection diagnosisThyroid glandDiseaseFibrous tissueParaffin sectionsPatientsHelpful cluesThyroid